SEC, FDA Ink Data-Sharing Pact to Scrutinize Life-Sciences Disclosures
A new memorandum of understanding facilitates the exchange of non-public information, enabling the SEC to more easily verify whether investor-facing statements by life sciences companies accurately reflect their communications with the FDA.
The U.S. Securities and Exchange Commission and the Food and Drug Administration have updated a memorandum of understanding to enhance the sharing of non-public information, signaling a coordinated effort to scrutinize public companies’ disclosures. The agreement modernizes protocols for exchanging data, allowing the SEC to more effectively investigate whether statements made by life sciences, pharmaceutical, and healthcare companies to investors align with their actual communications with the FDA.
Sophisticated counsel should view this as a significant increase in enforcement risk. The SEC can now more easily compare a company’s optimistic press releases about clinical trial results or pending product approvals against the FDA's internal and potentially more skeptical assessment. Discrepancies could trigger investigations and enforcement actions for misleading investors. Publicly-traded companies in FDA-regulated industries must now exercise even greater caution, ensuring that legal counsel with deep FDA experience meticulously reviews all investor-facing communications to ensure they are precise and accurately reflect the substance and tone of agency interactions. The key action is to align public narratives strictly with the regulatory reality.